Research
Research Solo Hemp Relief
- Skelley, J. W., Deas, C. M., Curren, Z., & Ennis, J. (2020). Use of cannabidiol in anxiety and anxiety-related disorders. Journal of the American Pharmacists Association, 60(1), 253–261. https://doi.org/10.1016/j.japh.2019.11.008
- Cascio, M. G., Gauson, L. A., Stevenson, L. A., Ross, R. A., & Pertwee, R. G. (2009). Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159(1), 129–141. https://doi.org/10.1111/j.1476-5381.2009.00515.x
- Croteau, E., Castellano, C.-A., Richard, M. A., Fortier, M., Nugent, S., Lepage, M., Duchesne, S., Whittingstall, K., Turcotte, É. E., Bocti, C., Fülöp, T., &; Cunnane, S. C. (2018). Ketogenic medium chain triglycerides increase brain energy metabolism in alzheimer’s disease. Journal of Alzheimer's Disease, 64(2), 551–561. https://doi.org/10.3233/jad-180202
- Anand, U., Jones, B., Korchev, Y., Bloom, S. R., Pacchetti, B., Anand, P., & Sodergren, M. H. (2020). CBD effects on TRPV1 signaling pathways in cultured DRG neurons. Journal of Pain Research, Volume 13, 2269–2278. https://doi.org/10.2147/jpr.s258433
- Evans, F. (1991). Cannabinoids: The separation of central from peripheral effects on a structural basis. Planta Medica, 57(S 1). https://doi.org/10.1055/s-2006-960231
- Russo E. B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and clinical risk management, 4(1), 245–259. https://doi.org/10.2147/tcrm.s1928
- Yu, S., Go, G. W., & Kim, W. (2019). Medium Chain Triglyceride (MCT) Oil Affects the Immunophenotype via Reprogramming of Mitochondrial Respiration in Murine Macrophages. Foods (Basel, Switzerland), 8(11), 553. https://doi.org/10.3390/foods8110553
- Martina Cirlini, Pedro Mena, Michele Tassotti, Kelli A Herrlinger et al. (2016). Phenolic and Volatile Composition of a Dry Spearmint (Mentha spicata L.) Extract. Molecules, 3;21(8).
Back to product
view certificate of analysis